glp 1 review The New GLP-1 and Anesthesia: Considerations and

Description

This triple mechanism produces greater weight loss, potentially better metabolic improvements, and additional effects like increased energy expenditure from glucagon activation

ISSN 0021-9258

Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade

What strategies can be employed to preserve lean body mass and mitigate weight regain after treatment discontinuation

Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Soliqua Patients naive to basal insulin or a GLP-1 agonist, currently on a GLP-1 agonist or less than 30 units of basal insulin daily: starting dose is 15 units once daily Patients currently on 30 to 60 units of basal insulin daily, with or without a GLP-1 agonist: starting dose is 30 units once daily Maintenance: titrate dose up or down by 2 - 4 units every week based on blood sugar goals Missed doses: resume dosing at the next scheduled dose